Salarius Pharmaceuticals (SLRX) Competitors $4.60 +0.42 (+10.05%) Closing price 04:00 PM EasternExtended Trading$4.57 -0.03 (-0.65%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SLRX vs. PRTG, ALZN, OBSV, TTNP, MYNZ, BCDA, BCLI, KZIA, CDIO, and PPBTShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include Portage Biotech (PRTG), Alzamend Neuro (ALZN), ObsEva (OBSV), Titan Pharmaceuticals (TTNP), Mainz Biomed (MYNZ), BioCardia (BCDA), Brainstorm Cell Therapeutics (BCLI), Novogen (KZIA), Cardio Diagnostics (CDIO), and Purple Biotech (PPBT). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Its Competitors Portage Biotech Alzamend Neuro ObsEva Titan Pharmaceuticals Mainz Biomed BioCardia Brainstorm Cell Therapeutics Novogen Cardio Diagnostics Purple Biotech Portage Biotech (NASDAQ:PRTG) and Salarius Pharmaceuticals (NASDAQ:SLRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation. Is PRTG or SLRX more profitable? Portage Biotech's return on equity of 0.00% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Portage BiotechN/A N/A N/A Salarius Pharmaceuticals N/A -556.47%-192.35% Do insiders and institutionals believe in PRTG or SLRX? 13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 11.9% of Salarius Pharmaceuticals shares are held by institutional investors. 42.1% of Portage Biotech shares are held by insiders. Comparatively, 1.2% of Salarius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable earnings and valuation, PRTG or SLRX? Portage Biotech is trading at a lower price-to-earnings ratio than Salarius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPortage BiotechN/AN/A-$6.77M-$41.65-0.18Salarius PharmaceuticalsN/AN/A-$5.58M-$43.48-0.11 Does the media favor PRTG or SLRX? In the previous week, Salarius Pharmaceuticals had 4 more articles in the media than Portage Biotech. MarketBeat recorded 4 mentions for Salarius Pharmaceuticals and 0 mentions for Portage Biotech. Salarius Pharmaceuticals' average media sentiment score of 0.97 beat Portage Biotech's score of 0.00 indicating that Salarius Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Portage Biotech Neutral Salarius Pharmaceuticals Positive Which has more volatility and risk, PRTG or SLRX? Portage Biotech has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, Salarius Pharmaceuticals has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500. SummaryPortage Biotech and Salarius Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.13M$2.96B$6.11B$10.46BDividend YieldN/A57.77%5.73%4.77%P/E Ratio-0.1122.7985.3627.36Price / SalesN/A756.67607.16135.99Price / CashN/A172.6337.4661.86Price / Book0.325.5112.426.81Net Income-$5.58M$33.06M$3.32B$276.80M7 Day Performance11.65%0.95%1.01%0.27%1 Month Performance-15.60%14.25%10.75%8.31%1 Year Performance-79.82%0.85%76.20%35.60% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals0.8772 of 5 stars$4.60+10.0%N/A-78.4%$2.13MN/A-0.1120PRTGPortage BiotechN/A$7.63+9.6%N/A+3.2%$8.01MN/A-0.186Gap UpHigh Trading VolumeALZNAlzamend Neuro2.1575 of 5 stars$2.54-0.8%$42.00+1,553.5%-85.2%$7.98MN/A0.004Analyst ForecastOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050TTNPTitan Pharmaceuticals0.7926 of 5 stars$5.93+23.7%N/A+21.5%$7.88MN/A-2.0110Positive NewsHigh Trading VolumeMYNZMainz Biomed2.682 of 5 stars$1.72+5.9%$14.00+716.3%-88.0%$7.86M$890K-0.0330Negative NewsAnalyst ForecastGap DownBCDABioCardia3.479 of 5 stars$1.35-3.9%$25.00+1,758.7%-40.2%$7.81MN/A-0.7340Gap DownBCLIBrainstorm Cell Therapeutics1.1666 of 5 stars$0.70+1.4%N/A-68.0%$7.72MN/A-0.2140Gap DownKZIANovogen3.4164 of 5 stars$7.57+11.7%$16.50+118.0%-65.3%$7.62M$2.31M0.0012CDIOCardio Diagnostics0.8345 of 5 stars$4.33-1.7%N/A-28.4%$7.61M$40K0.001PPBTPurple Biotech1.7324 of 5 stars$0.58-4.8%$33.00+5,589.7%-85.4%$7.45MN/A-1.3820Negative News Related Companies and Tools Related Companies PRTG Competitors ALZN Competitors OBSV Competitors TTNP Competitors MYNZ Competitors BCDA Competitors BCLI Competitors KZIA Competitors CDIO Competitors PPBT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLRX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
